PD-1 market price war ignites in the Red Sea who can grasp the opportunity?

At present, there are five kinds of PD-1 / PD-L1 products on the domestic market, including trepril monoclonal antibody (trade name: tuoyi) of Junshi biology, sindeli monoclonal antibody (trade name: dabushu) of Cinda biology, carrizu monoclonal antibody (trade name: Erika) of Hengrui medicine, pabolizhu monoclonal antibody (trade name: coreda) of mosadong and navuliu monoclonal antibody (trade name) of BMS : odivo Of course, there are also Baiji Shenzhou under research in China According to the previous news from Sina medicine, the PD-1 variety of Baiji Shenzhou will also be approved within this year Different from the traditional chemotherapy and targeted therapy, PD-1 immunotherapy is a new anti-tumor therapy concept, which can overcome the immunosuppression in patients and reactivate their own immune cells to kill tumors In 2030, the global PD1 / PDL1 drug market size can reach US $78.9 billion, and China can reach US $13.1 billion It can be said that the market space of PD-1 / PD-L in the future will be huge, but no matter how big the space is, each enterprise will inevitably fight price war in the face of the limited market space After all, in front of the huge market, each pharmaceutical enterprise's competition for PD-1 market is increasingly fierce, and the competition between PD-1 products has become white hot Therefore, how to occupy more market space while ensuring their own profits is an important issue for the sales team of each enterprise The price war comes to inquire the prices of several PD-1 models It can be found that compared with other countries' markets, the pricing in the mainland market of China is relatively low For example, the drugs O and K that have entered the market before such a case, the approved indications are advanced non-small cell lung cancer and melanoma respectively The pricing in China is half of that in the US market The price of PD-1 products of Cinda biology and Junshi biology in China is 7838 yuan / 100mg of dabershu and 7200 yuan / 240mg of tuoyi respectively Compared with the O and K drugs of foreign enterprises, the two products have price advantages, among which treprizumab is only 1 / 3 of the price of mosadong K drugs corresponding to the same indication The price of the PD-1 product of Hengrui medicine is higher than that of Xinda biology and Junshi biology At present, the price of Erica, the PD-1 product of Hengrui medicine in China, is 19800 yuan / bottle, the specification is 200mg, the treatment plan is once every two weeks, the price is higher than the price of PD-1 monoclonal antibody of Junshi biology and Xinda biology, However, according to the published drug donation scheme, the annual treatment cost of Erika can be as low as 118800 yuan, slightly higher than 100800 yuan of domestic PD-1 McAb zhongjunshi biological, but lower than 188000 yuan of Xinda biological As the industry unanimously regards the charity drug donation program as the final selling price of cancer drugs, it can be said that Hengrui's pricing is not completely uncompetitive In terms of sales volume, coreda's sales volume in the first half of this year is 1 billion yuan, and its performance in China is expected to exceed 2 billion yuan this year; odevo's potential is not to be underestimated, with sales volume of 430 million yuan in the first half of this year, which is expected to exceed 1 billion yuan this year; sales revenue of dabushu in the first half of this year is 332 million yuan, accounting for 95.98% of the total revenue; sales revenue of tuoyi in the first half of this year is 308 million yuan, accounting for 99.69% of the total revenue The growth of sales volume means the enhancement of market promotion For example, according to the data disclosed by Cinda bio in the semi annual report of 2019, as of June 30, the sales and marketing expenses of Cinda bio increased by 269.5 million yuan to 279.6 million yuan, accounting for 80% of the total sales revenue of Cinda bio in the first half of the year, which shows that the strength of market promotion is great In addition to the approved indications, major pharmaceutical companies are also competing for new indications for their products, and everyone has entered the stage of competing for time in research and development This can also be seen from the semi annual report just released, the semi annual report and related announcements disclosed by domestic PD-1 pharmaceutical companies Jun shibio said in the semi annual report that in the first half of the year, it carried out 11 phase II / phase III key clinical trials of the company's PD-1 product tuoyi, which were used in the adjuvant treatment of advanced melanoma, advanced esophageal cancer, advanced liver cancer, non-small cell lung cancer, advanced nasopharyngeal cancer and advanced urothelial cancer Cinda biology also said in the semi annual report that the company is carrying out more than 20 clinical studies on PD-1 Dabusu to assess its safety and effectiveness for a wide range of cancer indications, including eight registered or key clinical trials Three of these trials evaluated Dabusu for Two-line, one-line, and one-line NSCLC, and completed patient recruitment In the same way, Erica of Hengrui medicine is also expanding its indications On July 22, Hengrui medicine said on its official website that the company is carrying out 29 studies in China to evaluate the single drug or combination of different treatment methods of Erika, among which, the phase III clinical study for the treatment of advanced esophageal squamous cell carcinoma has been completed, the indications for HCC have been applied for listing based on the therapeutic efficacy and safety data obtained from phase II clinical trial and accepted by CDE, and have been included in the publicity list of the varieties to be prioritized for review 。 The fierce competition among pharmaceutical companies is bound to affect those who are not yet commercialized At present, there are more than 100 enterprises that are still studying PD-1 products in China Among them, Fuhong Hanlin and Baiji Shenzhou are well-known innovative pharmaceutical enterprises It can be said that at the stage when the domestic PD-1 market has become increasingly competitive, the enterprises that have not yet achieved commercialization will inevitably lose their first mover advantage After all, when the company's products are listed, they still need to snatch shares from the above-mentioned enterprises that have achieved commercialization However, in this case, it is tantamount to snatching food from the tiger's mouth After all, under the situation that the major enterprises have consolidated their sphere of influence, they are bound to pay more energy than the previous enterprises to expand their sales space Can I get medical insurance? On August 20, the regular access list of the new version of the national medical insurance catalog was finally issued However, due to the fact that a new list of drugs for negotiation and access has not yet been finalized, it remains a mystery whether the Internet red anticancer drug PD-1, which has attracted much attention from the outside world, can be included in the national health insurance catalog If PD-1 is not included in the medical insurance catalog, the impact on the above-mentioned enterprises will not be underestimated Making good use of the national medical insurance policy, enterprises will be more effective in occupying the market At present, the main resistance for PD-1 to enter the medical insurance catalog is that the price is relatively high and PD-1 products are expensive From the perspective of spending small money to do big things, medical insurance should protect the basic layer However, according to the data previously released by the health insurance bureau, in 2018, China's health insurance fund spent a total of 1.76 trillion yuan, with an average quarterly expenditure of 440 billion yuan, of which targeted drugs accounted for 0.24% of the health insurance expenditure It's hard to say that targeted cancer patients "crowd out" the medical resources of non cancer patients Moreover, the problem has already been solved in the local medical insurance catalogue On May 21, according to a notice on clarifying the catalogue of drugs (the third batch) for additional supplementary medical insurance malignant tumor self funded drug projects in Zhuhai issued by Zhuhai branch of China Life Insurance Co., Ltd According to the notice, tuoyi of Junshi biology and K medicine of mosadong are currently included in the reimbursement scope However, it is worth noting that the two PD-1 are included in the reimbursement scope Strictly speaking, it is not medical insurance reimbursement, but supplementary medical insurance beyond medical insurance It originates from the "great love and boundless" additional supplementary medical insurance project announced by Zhuhai human resources and Social Security Bureau on December 13, 2018 It has been officially implemented since 2019, with an annual premium of 190 yuan per person The premium can be purchased with the individual account fund or cash of medical insurance It can be seen that Zhuhai's local policies may provide some useful ideas for the relevant departments of the state After all, if PD-1 can be included in the national health insurance catalog, it can improve the accessibility of drugs Of course, PD-1 therapy is still a relatively new treatment for many clinicians, and the debate on whether to enter the medical insurance will continue.